Key Highlights

  • NextPlat (NASDAQ:NXPL) traded at USD 6.30 on November 12, 2026, down 24%, on about 41,810 shares, roughly twice its normal volume, with a Market Value near USD 17.09 million.
  • No company announcement was found for November 10 to 12, so the fall has no confirmed trigger; the float is only about 1.5 million shares.
  • Second-quarter Revenue rose about 21% from the first quarter to about USD 11.9 million, with a record gross Margin of about 40% and a net loss of about USD 144,000.
  • The company held about USD 11.9 million of cash at June 30, 2026 and completed a Pensacola-area pharmacy Acquisition in October.

A Sharp Move on a Small Float

NextPlat (NASDAQ:NXPL) runs two businesses: PharmcoRx pharmacies in Florida, which serve 340B contract, long-term care and prescription fulfilment customers, and an E-commerce and satellite device Business through its UK Subsidiary Global Telesat Communications. On November 12 its shares fell 24% to USD 6.30 on about 41,810 shares. That Volume was about twice the normal level, but still small in absolute terms, and with a float of only about 1.5 million shares, modest selling can move the price sharply. No press release, filing or contract news was found for November 10 to 12, and the third-quarter report has not yet been released. The most likely explanation is position adjustment ahead of results in a thinly traded stock, an interpretation rather than a confirmed cause. The decline erases much of the gain the stock made after its second-quarter report in August, when it rose 20.86% in a day. Small floats like this can also attract short-term traders whose exits exaggerate daily moves.

Operating Trends Have Improved

The latest reported quarter showed progress. Second-quarter revenue reached about USD 11.9 million, up about 21% from USD 9.9 million in the first quarter, and gross margin reached a record of about 40%. The net loss attributable to common shareholders narrowed to about USD 144,000, or USD 0.05 per share, from a loss of USD 1.1 million in the first quarter. The company held about USD 11.9 million of cash, Working Capital of about USD 14.2 million and total liabilities of about USD 12.2 million at June 30. In October it completed the purchase of a Pensacola-area pharmacy for about USD 1.49 million in cash, a profitable and debt-free business with about USD 5.6 million of sales in 2025, and opened a new pharmacy in Jacksonville. It also earned specialty pharmacy accreditation in July. The mix of pharmacy growth and a smaller e-commerce unit gives the company two revenue streams, although healthcare now accounts for the clear majority of sales.

Valuation and What to Watch

The screen shows trailing diluted losses of USD 3.70 per share, an improvement of 19.42% from a year earlier, which reflects past losses more than the recent near break-even quarter. Full-year 2025 revenue was USD 54.3 million, so a market value near USD 17.09 million is low relative to sales, partly because the business has struggled to turn revenue into consistent profit. Investors should watch the third-quarter report for revenue from the new pharmacies, gross margin trends, progress toward profitability and any change in the cash balance. A new e-commerce agreement signed in September could also contribute. With such a small float, the shares are likely to remain volatile in both directions until results provide fresh direction.

Where Things Stand

NextPlat (NASDAQ:NXPL) fell 24% to USD 6.30 on November 12, 2026 with no company news found, as selling hit a stock with a float of about 1.5 million shares ahead of third-quarter results. Recent revenue growth, a record gross margin and new pharmacy acquisitions support the business case, so the next report will be the key test.